Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker

Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas that can be classified into three molecular subtypes by gene expression profiling (GEP): GCB, ABC and unclassified. Immunohistochemistry-based cell of origin (COO) classification, as a surrogate for GEP, using thr...

Descripción completa

Detalles Bibliográficos
Autores: Batlle López, Ana, González de Villambrosía, Sonia, Francisco, Mazorra, Malatxeberria, Sefora, Sáez, Anabel, Montalbán, Carlos, Sánchez, Lydia, García, Joan, González Barca, Eva, López-Hernández, Andrés, Ruiz-Marcellan, M. Carmen, Mollejo, Manuela, Grande, Cristina, Richards, Kristy L., Hsi Eric D., Tzankov, Alexandar, Visco, Carlo, Xu-Monette, Zijun Y., Cao, Xin, Young, Ken H., Piris, Miguel A., Conde, Eulogio, Montes Moreno, Santiago
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2016
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/178663
Acceso en línea:https://hdl.handle.net/2445/178663
Access Level:acceso abierto
Palabra clave:Limfomes
Cèl·lules B
Immunoteràpia
Lymphomas
B cells
Immunotheraphy
id ES_1cc9719d567865fb3cfb8d8bd6b4cd4a
oai_identifier_str oai:recercat.cat:2445/178663
network_acronym_str ES
network_name_str España
repository_id_str
spelling Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible markerBatlle López, AnaGonzález de Villambrosía, SoniaFrancisco, MazorraMalatxeberria, SeforaSáez, AnabelMontalbán, CarlosSánchez, LydiaGarcía, JoanGonzález Barca, EvaLópez-Hernández, AndrésRuiz-Marcellan, M. CarmenMollejo, ManuelaGrande, CristinaRichards, Kristy L.Hsi Eric D.Tzankov, AlexandarVisco, CarloXu-Monette, Zijun Y.Cao, XinYoung, Ken H.Piris, Miguel A.Conde, EulogioMontes Moreno, SantiagoLimfomesCèl·lules BImmunoteràpiaLymphomasB cellsImmunotheraphyDiffuse large B cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas that can be classified into three molecular subtypes by gene expression profiling (GEP): GCB, ABC and unclassified. Immunohistochemistry-based cell of origin (COO) classification, as a surrogate for GEP, using three available immunohistochemical algorithms was evaluated in TMA-arranged tissue samples from 297 patients with de novo DLBCL treated by chemoimmunotherapy (R-CHOP and R-CHOP-like regimens). Additionally, the prognostic impacts of MYC, BCL2, IRF4 and BCL6 abnormalities detected by FISH, the relationship between the immunohistochemical COO classification and the immunohistochemical expression of MYC, BCL2 and pSTAT3 proteins and clinical data were evaluated. In our series, non-GCB DLBCL patients had significantly worse progression-free survival (PFS) and overall survival (OS), as calculated using the Choi, Visco-Young and Hans algorithms, indicating that any of these algorithms would be appropriate for identifying patients who require alternative therapies to R-CHOP. Whilst MYC abnormalities had no impact on clinical outcome in the non-GCB subtype, those patients with isolated MYC rearrangements and a GCB-DLBCL phenotype had worse PFS and therefore might benefit from novel treatment approaches.Impact Journals2021202120162021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion14 p.application/pdfapplication/pdfhttps://hdl.handle.net/2445/178663Articles publicats en revistes (Ciències Clíniques)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.18632/oncotarget.7495Oncotarget, 2016, vol. 7, num. 14, p. 18036-18049https://doi.org/10.18632/oncotarget.7495cc-by (c) Batlle López, Ana et al., 2016https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1786632026-05-29T05:05:01Z
dc.title.none.fl_str_mv Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
title Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
spellingShingle Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
Batlle López, Ana
Limfomes
Cèl·lules B
Immunoteràpia
Lymphomas
B cells
Immunotheraphy
title_short Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
title_full Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
title_fullStr Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
title_full_unstemmed Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
title_sort Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
dc.creator.none.fl_str_mv Batlle López, Ana
González de Villambrosía, Sonia
Francisco, Mazorra
Malatxeberria, Sefora
Sáez, Anabel
Montalbán, Carlos
Sánchez, Lydia
García, Joan
González Barca, Eva
López-Hernández, Andrés
Ruiz-Marcellan, M. Carmen
Mollejo, Manuela
Grande, Cristina
Richards, Kristy L.
Hsi Eric D.
Tzankov, Alexandar
Visco, Carlo
Xu-Monette, Zijun Y.
Cao, Xin
Young, Ken H.
Piris, Miguel A.
Conde, Eulogio
Montes Moreno, Santiago
author Batlle López, Ana
author_facet Batlle López, Ana
González de Villambrosía, Sonia
Francisco, Mazorra
Malatxeberria, Sefora
Sáez, Anabel
Montalbán, Carlos
Sánchez, Lydia
García, Joan
González Barca, Eva
López-Hernández, Andrés
Ruiz-Marcellan, M. Carmen
Mollejo, Manuela
Grande, Cristina
Richards, Kristy L.
Hsi Eric D.
Tzankov, Alexandar
Visco, Carlo
Xu-Monette, Zijun Y.
Cao, Xin
Young, Ken H.
Piris, Miguel A.
Conde, Eulogio
Montes Moreno, Santiago
author_role author
author2 González de Villambrosía, Sonia
Francisco, Mazorra
Malatxeberria, Sefora
Sáez, Anabel
Montalbán, Carlos
Sánchez, Lydia
García, Joan
González Barca, Eva
López-Hernández, Andrés
Ruiz-Marcellan, M. Carmen
Mollejo, Manuela
Grande, Cristina
Richards, Kristy L.
Hsi Eric D.
Tzankov, Alexandar
Visco, Carlo
Xu-Monette, Zijun Y.
Cao, Xin
Young, Ken H.
Piris, Miguel A.
Conde, Eulogio
Montes Moreno, Santiago
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Limfomes
Cèl·lules B
Immunoteràpia
Lymphomas
B cells
Immunotheraphy
topic Limfomes
Cèl·lules B
Immunoteràpia
Lymphomas
B cells
Immunotheraphy
description Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas that can be classified into three molecular subtypes by gene expression profiling (GEP): GCB, ABC and unclassified. Immunohistochemistry-based cell of origin (COO) classification, as a surrogate for GEP, using three available immunohistochemical algorithms was evaluated in TMA-arranged tissue samples from 297 patients with de novo DLBCL treated by chemoimmunotherapy (R-CHOP and R-CHOP-like regimens). Additionally, the prognostic impacts of MYC, BCL2, IRF4 and BCL6 abnormalities detected by FISH, the relationship between the immunohistochemical COO classification and the immunohistochemical expression of MYC, BCL2 and pSTAT3 proteins and clinical data were evaluated. In our series, non-GCB DLBCL patients had significantly worse progression-free survival (PFS) and overall survival (OS), as calculated using the Choi, Visco-Young and Hans algorithms, indicating that any of these algorithms would be appropriate for identifying patients who require alternative therapies to R-CHOP. Whilst MYC abnormalities had no impact on clinical outcome in the non-GCB subtype, those patients with isolated MYC rearrangements and a GCB-DLBCL phenotype had worse PFS and therefore might benefit from novel treatment approaches.
publishDate 2016
dc.date.none.fl_str_mv 2016
2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/178663
url https://hdl.handle.net/2445/178663
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.7495
Oncotarget, 2016, vol. 7, num. 14, p. 18036-18049
https://doi.org/10.18632/oncotarget.7495
dc.rights.none.fl_str_mv cc-by (c) Batlle López, Ana et al., 2016
https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Batlle López, Ana et al., 2016
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 14 p.
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Impact Journals
publisher.none.fl_str_mv Impact Journals
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404242624643072
score 15.812429

Similares en LA Referencia